NASDAQ:IRMD - Iradimed Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$28.42 +0.40 (+1.43 %)
(As of 04/25/2019 11:48 AM ET)
Previous Close$28.02
Today's Range$28.22 - $28.44
52-Week Range$15.56 - $38.78
Volume438 shs
Average Volume35,168 shs
Market Capitalization$312.62 million
P/E Ratio66.28
Dividend YieldN/A
Beta1.8
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; and MRI compatible patient vital signs monitoring system. The company also offers IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. It serves hospitals, acute care facilities, and outpatient imaging centers. The company sells its products through direct field sales representatives, regional sales directors, clinical support representatives, and independent distributors. IRADIMED CORPORATION was incorporated in 1992 and is headquartered in Winter Springs, Florida.

Receive IRMD News and Ratings via Email

Sign-up to receive the latest news and ratings for IRMD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:IRMD
CUSIPN/A
Phone407-677-8022

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$30.44 million
Cash Flow$0.6039 per share
Book Value$3.84 per share

Profitability

Net Income$6.30 million

Miscellaneous

Employees95
Market Cap$312.62 million
Next Earnings Date4/30/2019 (Confirmed)
OptionableNot Optionable

Iradimed (NASDAQ:IRMD) Frequently Asked Questions

What is Iradimed's stock symbol?

Iradimed trades on the NASDAQ under the ticker symbol "IRMD."

How will Iradimed's stock buyback program work?

Iradimed announced that its Board of Directors has approved a stock repurchase plan on Sunday, June 4th 2017, which allows the company to buyback $8,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to purchase shares of its stock through open market purchases. Stock buyback plans are generally an indication that the company's management believes its stock is undervalued.

How were Iradimed's earnings last quarter?

Iradimed Corp (NASDAQ:IRMD) issued its quarterly earnings results on Wednesday, February, 6th. The medical equipment provider reported $0.14 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.13 by $0.01. The medical equipment provider had revenue of $8.34 million for the quarter, compared to analysts' expectations of $8.19 million. Iradimed had a net margin of 20.71% and a return on equity of 13.78%. View Iradimed's Earnings History.

When is Iradimed's next earnings date?

Iradimed is scheduled to release their next quarterly earnings announcement on Tuesday, April 30th 2019. View Earnings Estimates for Iradimed.

What guidance has Iradimed issued on next quarter's earnings?

Iradimed issued an update on its first quarter 2019 earnings guidance on Wednesday, February, 6th. The company provided earnings per share guidance of $0.12-0.13 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.15. The company issued revenue guidance of $8.3-8.5 million, compared to the consensus revenue estimate of $9.1 million.Iradimed also updated its guidance to EPS.

What price target have analysts set for IRMD?

1 brokers have issued twelve-month price objectives for Iradimed's shares. Their forecasts range from $35.00 to $35.00. On average, they anticipate Iradimed's share price to reach $35.00 in the next year. This suggests a possible upside of 23.2% from the stock's current price. View Analyst Price Targets for Iradimed.

What is the consensus analysts' recommendation for Iradimed?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iradimed in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Iradimed.

Has Iradimed been receiving favorable news coverage?

News headlines about IRMD stock have trended somewhat positive this week, InfoTrie reports. The research group rates the sentiment of media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Iradimed earned a news sentiment score of 1.5 on InfoTrie's scale. They also assigned media coverage about the medical equipment provider a news buzz of 1.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days.

Who are some of Iradimed's key competitors?

What other stocks do shareholders of Iradimed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Iradimed investors own include NVIDIA (NVDA), Micron Technology (MU), Paypal (PYPL), Palo Alto Networks (PANW), ABIOMED (ABMD), BioTelemetry (BEAT), Cisco Systems (CSCO), IntriCon (IIN), Intuitive Surgical (ISRG) and GrubHub (GRUB).

Who are Iradimed's key executives?

Iradimed's management team includes the folowing people:
  • Mr. Roger E. Susi, Founder, Chairman, CEO & Pres (Age 66)
  • Mr. Christopher K. Scott, CFO & Sec. (Age 49)
  • Mr. John McCreery, Chief Operating Officer (Age 64)
  • Mr. Brent Johnson, Exec. VP of Worldwide Sales & Marketing (Age 60)
  • Mr. Louis Waldman, Controller (Age 64)

Who are Iradimed's major shareholders?

Iradimed's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Oppenheimer Asset Management Inc. (0.02%). Company insiders that own Iradimed stock include Brent Johnson, Christopher K Scott, Francis X Casey, John K Mccreery, Louis S Waldman, Monty K Allen, Roger E Susi and Steven M Nardi. View Institutional Ownership Trends for Iradimed.

Which major investors are buying Iradimed stock?

IRMD stock was acquired by a variety of institutional investors in the last quarter, including Oppenheimer Asset Management Inc.. View Insider Buying and Selling for Iradimed.

How do I buy shares of Iradimed?

Shares of IRMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Iradimed's stock price today?

One share of IRMD stock can currently be purchased for approximately $28.42.

How big of a company is Iradimed?

Iradimed has a market capitalization of $312.62 million and generates $30.44 million in revenue each year. The medical equipment provider earns $6.30 million in net income (profit) each year or $0.43 on an earnings per share basis. Iradimed employs 95 workers across the globe.

What is Iradimed's official website?

The official website for Iradimed is http://www.iradimed.com.

How can I contact Iradimed?

Iradimed's mailing address is 1025 Willa Springs Dr., Winter Springs FL, 32708. The medical equipment provider can be reached via phone at 407-677-8022 or via email at [email protected]


MarketBeat Community Rating for Iradimed (NASDAQ IRMD)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  193 (Vote Outperform)
Underperform Votes:  200 (Vote Underperform)
Total Votes:  393
MarketBeat's community ratings are surveys of what our community members think about Iradimed and other stocks. Vote "Outperform" if you believe IRMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IRMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/25/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel